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Mitochondrial ADP/ATP exchange 
inhibition: a novel off-target 
mechanism underlying ibipinabant-
induced myotoxicity
Tom J. J. Schirris1,2, Tina Ritschel3, G. Herma Renkema2,4, Peter H. G. M. Willems2,5, 
Jan A. M. Smeitink2,4 & Frans G. M. Russel1,2
Cannabinoid receptor 1 (CB1R) antagonists appear to be promising drugs for the treatment of 
obesity, however, serious side effects have hampered their clinical application. Rimonabant, the first 
in class CB1R antagonist, was withdrawn from the market because of psychiatric side effects. This 
has led to the search for more peripherally restricted CB1R antagonists, one of which is ibipinabant. 
However, this 3,4-diarylpyrazoline derivative showed muscle toxicity in a pre-clinical dog study with 
mitochondrial dysfunction. Here, we studied the molecular mechanism by which ibipinabant induces 
mitochondrial toxicity. We observed a strong cytotoxic potency of ibipinabant in C2C12 myoblasts. 
Functional characterization of mitochondria revealed increased cellular reactive oxygen species 
generation and a decreased ATP production capacity, without effects on the catalytic activities of 
mitochondrial enzyme complexes I–V or the complex specific-driven oxygen consumption. Using in 
silico off-target prediction modelling, combined with in vitro validation in isolated mitochondria and 
mitoplasts, we identified adenine nucleotide translocase (ANT)-dependent mitochondrial ADP/ATP 
exchange as a novel molecular mechanism underlying ibipinabant-induced toxicity. Minor structural 
modification of ibipinabant could abolish ANT inhibition leading to a decreased cytotoxic potency, as 
observed with the ibipinabant derivative CB23. Our results will be instrumental in the development of 
new types of safer CB1R antagonists.
Nowadays, overweight and obesity are worldwide one of the greatest health challenges1. Compared to 
other modifiable cardiovascular risk factors, obesity is still a poorly understood condition for which 
treatment options remain elusive2. Overstimulation of the endocannabinoid system, which plays an 
important role in metabolism and energy balance, has been associated with obesity3,4. Signalling in this 
system is mainly mediated through both centrally and peripherally expressed cannabinoid-1 receptors 
(CB1R)5,6. CB1R antagonists appeared to be beneficial in rodent models of obesity, leading to reduced 
food intake and body weight7,8. Similar effects were also observed in clinical trials with rimonabant, the 
only approved CB1R antagonist for therapeutic use9. The drug was, however, rapidly withdrawn from the 
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market after the observation of serious neuropsychiatric side effects, which could mainly be attributed to 
central nervous system effects by rimonabant’s ability to pass the blood-brain barrier10.
The demand for a therapy to counteract obesity, combined with multiple other beneficial effects on 
plasma triglyceride levels, fasting insulin and glucose levels, and β -cell function in diabetes, has led to the 
search for peripherally restricted CB1R antagonists4,7. This was based on the observation that reduction 
of food intake could also be accomplished through a mechanism independent of central CB1R occu-
pancy, thereby avoiding the neuropsychiatric side effects7,8,11. These effects may be partially explained 
by the capacity of peripheral CB1R antagonists to lower leptin expression and secretion by adipocytes, 
combined with an increased renal leptin clearance12. Consequently, hyperleptinemia observed with obe-
sity is reversed, which leads to reduced hypothalamic endocannabinoid levels, thereby indirectly affecting 
central appetite regulation13.
Compared to rimonabant, which is a 1,5-diarylpyrazole derivative, the 3,4-diarylpyrazoline ibipina-
bant (S-SLV-319) showed substantially lower levels of centrally occupied CB1R (11% vs. 80%), which 
might be due to a lower passage of the blood-brain barrier11,14. Therefore, ibipinabant was used as a 
template for the development of several novel 3,4-diarylpyrazoline CB1R antagonists8,11.
During preclinical development of ibipinabant, however, striated-muscle toxicity was observed in 
a dog-study, which was shown to be CB1R independent15. The authors attributed the evident mito-
chondrial dysfunction to the inhibition of flavin-containing enzymes, as concluded from a metabolic 
pattern matching ethylmalonic-adipic aciduria in humans15. However, the exact mechanism underlying 
ibipinabant-induced myopathy remains unresolved.
Here, we unravelled the effect of ibipinabant on mitochondrial function in C2C12 myoblasts. We 
found increased generation of cellular reactive oxygen species (ROS) and decreased ATP production 
capacity, which was linked to an increased mitochondrial membrane potential. By in silico off-target 
modelling we could predict both the voltage-dependent anion channel (VDAC) and the adenine nucle-
otide translocase 1 (ANT1) as the potential molecular site of ibipinabant inhibition. This in silico pre-
diction was experimentally verified by a decreased mitochondrial ATP/ADP exchange. Moreover, these 
effects could be abolished by minor structural modification of ibipinabant.
Results
Ibipinabant is a potent inducer of cytotoxicity in C2C12 myoblasts accompanied by mito-
chondrial dysfunction. To gain more insight into the mechanisms underlying ibipinabant-induced 
myotoxicity, we used C2C12 murine myoblasts as a cell model. Already after 24 hours of exposure 
to increasing concentrations of ibipinabant, cell viability was significantly (P=1.61·10-7) decreased to 
73 ± 5% at the highest concentration tested (100 μ M, Fig. 1A). After 48 hours of exposure only 33 ± 4% 
of the cells remained viable at this concentration (Fig.  1B). The validity of our model was confirmed 
by the potent inhibition of cell viability by the known mitochondrial toxicant etoposide. At the highest 
concentration of 100 μ M 42 ± 6% cells remained viable after 24 hours (Fig. 1A), which further decreased 
to 7 ± 3% after 48 hours (Fig. 1B).
Next, we determined the effects of ibipinabant on mitochondrial function by measuring cellular ROS 
generation. A more than 2-fold increase could already be observed after 8 hours exposure with the high-
est ibipinabant concentration of 100 μ M compared to the vehicle treated C2C12 myoblasts (Fig. 2A,B). 
Figure 1. Ibipinabant-induced cytotoxicity in C2C12 myoblasts after 24 and 48 hours exposure. The 
number of cells was determined after 24 (A) and 48 (B) hours exposure of C2C12 myoblasts to increasing 
ibipinabant (•) concentrations. As a positive control, cells were exposed to etoposide (◦), a known inducer 
of mitochondria-mediated cell death. Cell viability was determined as the percentage of cells compared 
to vehicle control. Statistical analysis: one-way ANOVA with Dunnett’s post hoc analysis was applied 
to compare values to vehicle control **p < 0.01, ***p < 0.001. Mean ± SEM; n = 18 (3 independent 
experiments); IC50 values are plotted as mean with 95%-CI.
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We also investigated maximal mitochondrial ATP production capacity after permeabilisation of the 
C2C12 myoblasts (Fig.  2C). As indicated by the low IC50 value, a rapid decrease of ATP production 
capacity was observed after 4 hours incubation with increasing concentrations of ibipinabant (Fig. 2C).
Ibipinabant exposure affects mitochondrial coupling without alteration of complex I-V activ-
ity or respiratory capacity. A possible explanation for a decrease in ATP production capacity, 
accompanied by an increased generation of cellular ROS, could be inhibition of one of the enzyme 
complexes of the respiratory chain (complexes I–V). To examine this assumption we measured the oxy-
gen consumption in C2C12 myoblasts after 4 hours of pre-incubation with ibipinabant (1–100 μ M). In 
intact cells we did not observe a statistically significant effect of ibipinabant (see Supplementary Fig. S1 
online). To investigate whether one of the specific complexes might be affected by ibipinabant under 
maximal stimulation, we used complex specific substrates to measure oxygen consumption in permeabi-
lised C2C12 myoblasts (see Supplementary Fig. S1 online). However, none of the specific complex-driven 
respiratory rates was different from control. To be able to exclude any influence of 4 hours ibipinabant 
treatment on these complexes we also determined their catalytic activity and in agreement with the 
absence of effects on oxygen consumption, no effects could be observed on the enzyme activities (see 
Supplementary Fig. S1 online).
Uncoupling of oxidative phosphorylation is one of the explanations for the absence of an effect of 
ibipinabant on the enzyme complexes of the respiratory chain with a decreased ATP production16. The 
respiratory chain and mitochondrial ATP production, which together are referred to as oxidative phospho-
rylation, are coupled through the mitochondrial membrane potential (Ψ m ), providing the proton motive 
Figure 2. Ibipinabant leads to increased generation of reactive oxygen species and decreased 
mitochondrial ATP production. (A) ROS generation was measured after 8 hours exposure of C2C12 
myoblasts to ibipinabant using CM-H2DCFDA. (B) Followed by quantification of the CM-DCF intensity 
compared to vehicle control (640 ± 230 IU/cellular pixel) for increasing ibipinabant concentrations. 
Mean ± SEM; n = 12 (3 independent experiments); IC50 values are plotted as mean with 95%-CI. (C) 
Maximal ATP production was measured in permeabilised C2C12 cells after 4 hours of incubation with 
various ibipinabant concentrations. Data are expressed as percentage of vehicle (22 ± 6 nmol/h/mU CS). 
Mean ± SEM; n = 3 independent experiments; IC50 values are plotted as mean with 95%-CI. Statistical 
analysis: one-way ANOVA with Dunnett’s post hoc analysis was applied to compare values to vehicle control 
*p < 0.05, **p < 0.01.
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force needed for ATP production at mitochondrial complex V. Indeed, Ψ m appeared to be increased after 
4 hours of incubation with 100 μ M ibipinabant (Fig. 3A). An increase in Ψ m could already be observed 
at low ibipinabant concentrations (EC50 1.5 95%− CI: 0.7–3.1 μ M) (Fig. 3B). Such an increased Ψ m could 
be indicative of a decreased function of complex V in intact mitochondria, following from the decreased 
ATP production capacity. Together with the absence of an effect on the catalytic activity of complex V, 
under excess substrate conditions (see Supplementary Fig. S1 online), these findings point at a decreased 
ADP availability in the mitochondrial matrix.
Ibipinabant inhibits mitochondrial ANT-mediated ADP/ATP exchange. To address this pos-
sibility, in silico off-target predictions were performed to search for similarities between protein-ligand 
binding sites with the structure-based pharmacophore method KRIPO, possibly identifying off-targets 
involved in mitochondrial ADP/ATP exchange17. Each protein-ligand binding site is defined via the 
ligand of the complex followed by translation of the properties of the surrounding amino acids of the 
proteins into pharmacophore features, which are stored in bit strings called fingerprints. The finger-
prints allow fast computational comparison of all publically available structures in the Protein Data Bank 
(pdb)18. Since for CB1R no experimental structure is available, a homology model of the receptor was 
build. From the list of similar targets obtained by KRIPO, targets that could play a key role mitochon-
drial ADP/ATP exchange (adenine nucleotide translocase 1 (ANT1), voltage-dependent anion channel 
(VDAC), and mitochondrial complex V) were manually selected.
Of these three targets, an effect of ibipinabant on mitochondrial complex V could be excluded 
from our previous observations (see Supplementary Fig. S1 online). To investigate whether ibipinabant 
can actually fit into ANT1, the drug was docked into the binding pocket of the protein binding sites 
(Fig. 4). In the co-crystallised complex the binding site is occupied by the inhibitor carboxyatractyloside 
(Fig.  4B), a ten times more potent inhibitor compared to atractyloside, which was used in the exper-
iments described below19. These docking runs suggested that binding of ibipinabant to ANT1 appears 
likely, and a possible binding mode is illustrated (Fig.  4C). Whether ibipinabant would fit into VDAC 
could not be determined, because reliable docking was not possible due to the structural properties of 
the channel, e.g. having a large pore allowing unselective transport of many compounds.
The in silico predictions were experimentally verified by measuring ADP uptake into isolated 
bovine heart mitochondria (Fig. 5). This resulted in a significant (p = 0.041) decrease of mitochondrial 
VDAC-dependent ADP import after direct ibipinabant application (Fig.  5B). A similar effect could be 
observed on the ANT-dependent mitochondrial ADP uptake (Fig.  5A). Such an effect on both trans-
membrane transporters could be explained by the formation of a complex spanning the inner and outer 
mitochondrial membrane, as described previously20. The observations in intact bovine heart mitochon-
dria (containing both ANT and VDAC), could therefore not distinguish which of these transporters 
contributed to the effects of ibipinabant on ATP production and Ψ m.
To investigate whether the observed ibipinabant-induced decrease in mitochondrial ADP/ATP 
exchange was due to inhibition of either ANT or VDAC, C2C12 mitoplasts (mitochondria without outer 
membrane) were isolated to exclude any effects of VDAC, followed by determination of the maximal 
CI- and CII-specific respiratory rates (Fig.  6). Although CI-specific respiration was only moderately 
Figure 3. Mitochondrial membrane potential is increased after 4 hours ibipinabant exposure. 
(A) Mitochondrial membrane potential was measured by loading mitochondria with the cationic dye 
tetramethylrodamine methyl ester (TMRM) after 4 hours exposure of C2C12 myoblasts to ibipinabant. 
(B) Followed by quantification of the TMRM intensity compared to vehicle control (13.1 ± 0.3 IU/cellular 
pixel) at increasing ibipinabant concentrations. Statistical analysis: one-way ANOVA with Dunnett’s post 
hoc analysis was applied to compare values to vehicle control ***p  < 0.001. Mean ± SEM; n = 60–80 (4 
independent experiments); IC50 values are plotted as mean with 95%-CI.
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affected after direct ibipinabant addition, a significant (P=0.038) inhibition was found for CII-specific 
respiratory rates. These effects were also in line with the tendency towards a decreased routine respira-
tion (see Supplementary Fig. S1 online), which also indicated that mitoplasts were more sensitive than 
intact mitochondria to ibipinabant-induced respiratory inhibition. It also provided a firm indication that 
ibipinabant mainly reduced respiration by inhibition of the ANT-mediated ADP/ATP exchange.
Minor structural modification of ibipinabant abolishes ANT and VDAC inhibition. Finally, we 
compared the inhibitory effects of ibipinabant on mitochondrial ADP import with the closely related 
3,4-diarylpyrazoline derivative, CB23 (Fig.  7B). Replacement of the chlorophenyl group of ibipinabant 
with a 1,1-dioxo-thiomorpholine group (Fig. 7A,B), completely abolished the inhibitory effect on VDAC- 
and ANT-dependent mitochondrial ADP import (Fig. 7C,D). Moreover, CB23 exhibited a significantly 
lower cytotoxic potential as compared to ibipinabant (IC50 values: 188 vs 17 μ M, P=0.034, for 95%-CI 
see Fig. 7E). These findings also support that the cytotoxic effects observed with ibipinabant are related 
to inhibition of the ANT-dependent ADP/ATP exchange.
Discussion
We report that ibipinabant inhibits the mitochondrial ADP/ATP exchange ratio and thereby provide a 
plausible mechanism for the previously observed striated muscle toxicity in a pre-clinical dog study15. We 
could show that these effects occur after direct exposure, leading to a rapid decrease in ATP production, 
which we hypothesize to be due to decreased ADP content in the mitochondrial matrix. The accompa-
nied reduction in use of protons from the mitochondrial inner membrane space by complex V leads to 
an increase in Ψ m, if the complexes of the oxidative phosphorylation chain retain their outward proton 
motive force. Both effects could indeed be observed after treating C2C12 cells for 4 hours with ibipina-
bant. An increased Ψ m combined with a decreased ATP production are both characteristic for the initial 
phase of apoptosis21. This phase is followed by a collapse of the mitochondrial membrane potential and 
decreased oxygen consumption, explaining the increased cellular ROS levels after 8 hours of ibipinabant 
exposure, eventually initiating the cytotoxicity observed after 24 and 48 hours. Interestingly, the increased 
ROS levels and observed cytotoxicity resulted in much higher IC50 values, as compared to the effects on 
Figure 4. X-ray structure of ANT1 compared to a possible ibipinabant docking pose. (A) X-ray structure 
of ANT1 (pdb-code 2c3e) displayed as ribbon are colored from blue (N-terminus) to red (C-terminus) (B) 
ANT1 with a known inhibitor carboxyatractyloside (grey). (C) A possible docking pose of ibipinabant (pink) 
to ANT1.
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Figure 5. Ibipinabant-induced inhibition of ANT- and VDAC-dependent mitochondrial ADP uptake. 
Mitochondrial uptake of radiolabeled ADP was measured in bovine heart mitochondria with and without 
the model inhibitors (A) atractyloside (50μ M) and (B) DIDS (500 μ M) to determine ANT- and VDAC-
dependent ADP uptake, respectively. The effects of direct administration of 100 μ M ibipinabant were 
investigated under both conditions. Values presented are expressed as the percentage of vehicle control (delta 
cumulative counts, with and without model inhibitor): 1.61·104 ± 0.10·104 for ANT, and 1.70·104 ± 0.10·104 
for VDAC. Statistical analysis: Student’s t-test was applied to compare values to vehicle control *p < 0.05. 
Mean ± SEM; n = 4 independent experiments.
Figure 6. Ibipinabant-induced inhibition of respiratory capacity in mitoplasts. C2C12 mitoplasts 
were obtained by differential centrifugation of (sub)cellular fractions. Maximal respiratory capacity was 
determined after acute exposure to 100 μ M ibipinabant either by stimulation of (A) CI- or (B) CII-driven 
respiration. Effects of VDAC were excluded by the addition of 250 μ M DIDS, resulting in complete 
inhibition of VDAC-dependent respiration. The data presented are expressed as percentage of vehicle-treated 
control (pmolO2/s/mg protein): 14 ± 2 for CI, 25 ± 1 for CII. Statistical analysis: Student’s t-test was applied 
to compare values to vehicle control *p < 0.05. Mean ± SEM; n = 3 independent experiments.
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ATP production capacity and mitochondrial membrane potential. This difference could be explained by 
the presence of compensatory mechanisms, such as up-regulation of cellular anti-oxidant systems affect-
ing the former observations, which further demonstrates the major role of altered ADP/ATP exchange, 
and not the increased ROS levels, in the cytotoxic effects of ibipinabant.
Inhibition of mitochondrial ADP/ATP exchange can also explain the decreased fatty acid oxidation 
with concomitant lipid accumulation in the muscles, which was associated with ibipinabant-induced 
myotoxicity in the dog15. Decreased mitochondrial oxidative metabolism due to limited supply of ADP, 
will likely also decrease fatty acid oxidation. This could lead to accumulation of fatty acids, particularly 
in tissues like muscle, which heavily rely on oxidative metabolism and particularly fatty acid oxidation22. 
Although our results are in agreement with the effects described in dogs, it should be noted that C2C12 
Figure 7. Ibipinabant derivative 23 (CB23) does not inhibit ANT- and VDAC-dependent mitochondrial 
ADP uptake and has a low cytotoxic potency. The effect of structural modification of (A) ibipinabant 
on mitochondrial ADP uptake was investigated using (B) CB23. This derivative was obtained by 
replacing the chlorophenyl group by a 1,1-dioxo-thiomorpholine group (marked in red). The effects of 
direct administration of 100 μ M CB23 were investigated both for (C) ANT- and (D) VDAC-dependent 
mitochondrial ADP uptake. Experimental procedures and calculations were as described in Fig. 6. Statistical 
analysis: Student’s t-test was applied to compare values to vehicle control, no significant differences were 
observed. Mean ± SEM; n = 5 independent experiments. (E) The number of cells was determined after 
24 hours exposure of C2C12 myoblasts to increasing CB23 (■) concentrations. As a positive control, cells 
were exposed to etoposide (◦), a known inducer of mitochondria-mediated cell death. Cell viability was 
determined as described in Fig. 1. Statistical analysis: one-way ANOVA with Dunnett’s post hoc analysis was 
applied to compare values to vehicle control **p < 0.01, ***p < 0.001. Mean ± SEM; n = 18 (3 independent 
experiments); IC50 values are plotted as mean with 95%-CI.
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myoblasts express a functional CB1R, whereas the dog striated muscle does not15,23. However, previous 
studies have shown that stimulation, and not inhibition, of CB1R induced mitochondrial dysfunction. 
The use of AM251, a full CB1R antagonist like ibipinabant, completely reversed the CB1R-mediated 
mitochondrial dysfunction under these conditions. This points to a protective rather than a toxic effect 
of CB1R blockade, excluding a role of CB1R with regard to our observations24–26.
Although high ibipinabant concentrations were used in this study, they are in the range of the micro-
molar peak plasma concentrations previously observed in mice after an oral dose of 100 mg/kg for three 
consecutive days27. Furthermore, the observed muscle toxicity in dogs occurred after chronic exposure 
of a 3-fold higher daily dose (300 mg/kg for 13 weeks), which due to the lipophilic nature of ibipinabant 
may even have led to accumulation in the muscles15.
Based on the in silico off-target predictions and docking runs, ANT1 inhibition by ibipinabant is the 
most likely explanation for the decreased ADP import into the mitochondria, although an inhibitory 
effect on the VDAC channel cannot be fully excluded. They both play a pivotal role in mitochondrial 
ADP/ATP exchange28, and are hypothesized to interact with each other to form a complex, in which ANT 
embedded in the mitochondrial inner membrane is probably directly connected with VDAC located in 
the outer membrane20. However, using mitoplasts, we could separate the effects on both proteins and 
demonstrate that ibipinabant indeed inhibited ANT-dependent respiratory capacity. This is confirmed 
by a mouse ANT-/- knockout model, which also demonstrates mitochondrial dysfunction and mito-
chondrial myopathies29,30. Although ANT seems to be a more probable binding site of ibipinabant than 
VDAC, mutation studies or co-crystallisation should provide the final proof.
The absence of mitochondrial ADP import inhibition by the ibipinabant derivative CB23 empha-
sizes that minor structural modifications could determine the occurrence of off-target muscle toxic-
ity. Previously, we selected CB23 from a series of 3,4-diarylpyrazoline CB1R antagonists to proof the 
concept that its properties as a substrate of the efflux transporters P-glycoprotein and BCRP (breast 
cancer resistance protein), limits brain penetration and can be exploited to develop peripherally acting 
antagonists31,32. The observed effects of ibipinabant on mitochondrial ADP/ATP exchange could also be 
relevant for the development of other new CB1R antagonists based on ibipinabant8,11. Other new, periph-
erally restricted, CB1R antagonists are derivatives of ibipinabant in which either the 4,5-dihydropyrazole 
moiety or the central N-methyl group was replaced with polar pendants8,11. Of the latter category, com-
pounds JD5006 and JD5037, seemed to have the best efficacy in inhibition of CB1R and food intake8,11,27. 
Both antagonists showed a strong inhibitory potency against the CB1R, which was highest for JD5037 
that recently received the status of investigational new drug. It might therefore be needed to carefully 
consider their effects on mitochondrial ADP/ATP exchange, when these compounds are further evalu-
ated for therapeutic use. Moreover, based on the similarities between the CB1R and ANT1 binding sites, 
other CB1R antagonists could also have the potential to inhibit ANT1.
In conclusion, we revealed the mechanism underlying the off-target effect of ibipinabant-induced 
myotoxicity. This mechanism may be relevant for newly developed peripherally restricted CB1R antago-
nist, and an altered mitochondrial ADP/ATP exchange should be taken into consideration during further 
development of these compounds.
Methods
Compounds. Ibipinabant (S-SLV 319) was ordered at Cayman Chemical (Ann Arbor, MI). A racemic 
mixture of 3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide derivate 23 (CB23) 
was kindly provided by Abbott Products GmbH (Hannover, Germany). Etoposide, 4,4′ -diisothiocyana-
tostilbene-2,2′ -disulfonicacid disodium salt hydrate (DIDS), and atractyloside sodium salt were from 
Sigma Aldrich (Zwijndrecht, The Netherlands).
Cell culture. C2C12 murine myoblasts (CRTL 1772) were obtained from American Type Culture 
Collection (Wesel, Germany). C2C12 cells were maintained in Dulbecco’s modified Eagle’s medium with 
Glutamax I formulation containing 25 mM glucose and 25 mM HEPES supplemented with 10% (v/v) 
fetal calf serum (MP Biomedicals, Santa Ana, CA) at 37 °C in a humidified atmosphere of 5% CO2.
Analysis of cell death. C2C12 myoblasts were seeded in 384-wells black/clear imaging plates at 
a density of 4,000 cells/well, 24 hours prior to ibipinabant treatment. A 1,000× concentrated serial 
√10-dilution in DMSO was made for ibipinabant and the positive control etoposide. Immediately before 
use, ibipinabant and etoposide stock solutions were diluted 100× in phosphate buffered saline (PBS) and 
10× in the culture medium, resulting in a final DMSO concentration of 0.1% (v/v). Four replicates of each 
compound were tested up to maximum solubility (100 μ M). After 24 h and 48 h exposure, nuclei were 
stained for cell viability analysis using Hoechst 33342. After 20 minutes of staining at 37 °C, fluorescence 
was imaged on a BD Pathway 855 high-throughput microscope (Becton Dickinson (BD) Bioscience, 
Breda, The Netherlands). Followed by the analysis of the number of nuclei using Cellprofiler33.
Analysis of cellular reactive oxygen species. C2C12 myoblasts were seeded in 384-wells black/
clear imaging plates as described for analysis of cell death. After 8 hours of ibipinabant exposure cells 
were loaded with 10 μ M CM-H2DCFDA in HEPES-Tris (HT) buffer (132 mM NaCl, 10 mM HEPES, 
4.2 mM KCl, 1 mM MgCl2, 1 mM CaCl2 and 25 mM D-glucose, adjusted to pH 7.4 with Tris) for 
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20 minutes at 37 °C. Next, the cells were washed twice with HT buffer and imaged on a BD Pathway 855 
high-throughput microscope. CM-DCF images were processed using Image Pro Plus 6.3 software (Media 
Cybernetics, Silver Spring, MD). A mask of the images was made to separate the cellular pixels from the 
background; afterwards average CM-DCF intensity per cellular pixel was determined.
Mitochondrial ATP production capacity. After 4 hours ibipinabant exposure, C2C12 cells were 
resuspended in PBS with 3% bovine serum albumin, to a final density of 10·106 cells/mL. Next, mito-
chondrial ATP production from pyruvate was measured with 1.105 cells per incubation in the presence 
of 20 μ g digitonin/105 cells in duplicate as described previously34–36. All values were normalized to the 
activity of the mitochondrial matrix enzyme, citrate synthase, to correct for differences in mitochondrial 
mass. Citrate synthase was determined spectrophotometrically in duplicate as described before35.
Analysis of cellular and mitochondrial respiration. For measurement of the cellular respiration 
rate, 1.5·106 C2C12 cells were resuspended in mitochondrial respiration medium MiR05 after 4 hours 
ibipinabant exposure, and transferred to the thermostated (37 °C) chamber of an Oxygraph-2k equipped 
with Datlab 5 recording and analysis software (Oroboros Instruments, Innsbruck, Austria). Mitochondrial 
respiration driven by the separate respiratory chain complexes was measured after digitonin permeabi-
lisation (10 μ g/1·106 cells) of the cell membrane in MiR05 containing complex-specific substrates and 
4 mM ADP37. Glutamate (10 mM) plus malate (2 mM) were used as substrates for complex I (CI), suc-
cinate (10 mM) for CII, and ascorbate (2 mM) plus TMPD (0.5 mM) for CIV. CIII-driven respiration 
was measured in the presence of glycerophosphate (20 mM) and flavine adenine dinucleotide (10 μ M). 
Rotenone (0.5 μ M) and atpenin A5 (50 nM) were added to inhibit CI and CII, respectively. Cytochrome 
c (10 μ M) was added to check the integrity of the mitochondrial outer membrane. Finally, antimycin A 
(2,5 μ M) was added to completely block CIII-driven respiration. Mitoplasts were isolated from C2C12 
myoblasts to determine CI- and CII-specific respiration. Briefly, pellets of 10·106 cells were resuspended 
in 10 mM Tris-HCl and pottered, and sucrose was added (215 mM). The lysate was cleared of unbro-
ken cells by centrifugation (10 minutes 600 g), after which the supernatant containing the mitochondria 
was pelleted at 14,000 g for 10 minutes. Next, mitochondria were resuspended in hypotonic buffer (2% 
essential fatty acid free BSA, 20 mM K2HPO4, pH 7.4) and allowed to swell for 30 minutes, as described 
previously38, and subsequently pottered to remove the outer membrane. Mitoplasts were obtained from 
the lysate by centrifugation at 14,000 g for 15 minutes, followed by resuspension of the pellet in MiR05. 
At the start of the experiment DIDS (250 μ M) was added, just after the addition of cytochrome c, to 
exclude any influence of VDAC, and followed by determination of the CI- and CII-specific respiration 
as described above. Respiratory rates were normalized to mg protein in the mitoplast fractions as deter-
mined in duplicate by a Biorad protein assay (Biorad), after three sequential freeze thaw cycles to disrupt 
the inner membrane. Finally, all respiratory rates were corrected for non-mitochondrial respiration by 
subtraction of the residual respiratory rates after rotenone or antimycin A addition.
Catalytic capacity of individual OXPHOS complexes. After 4 hours ibipinabant exposure, C2C12 
pellets of 20·106 cells were snap frozen in liquid nitrogen and kept at − 80 °C until use. For mitochondrial 
preparations, cells were resuspended in 10 mM Tris-HCl and pottered, and sucrose was added (215 mM). 
The lysate was cleared of unbroken cells by centrifugation (10 minutes 600 g) after which the supernatant 
containing the mitochondria was pelleted at 14,000 g for 10 minutes, resuspended in 10mM Tris-HCl (pH 
7.6), and snap frozen in aliquots. Catalytic capacity of OXPHOS complexes was measured spectrophoto-
metrically in duplicate, as described previously39–41. Complex I-IV values were normalized to the activity 
of the mitochondrial matrix enzyme, citrate synthase, to correct for differences in mitochondrial mass. 
Citrate synthase was determined spectrophotometrically in duplicate as described before35. Complex V 
values were normalized to cytochrome c oxidase (COX, complex IV) activity.
Analysis of mitochondrial membrane potential. C2C12 cells (5.0·104) were seeded in 35 mm 
Fluorodishes (World Precision Instruments, Sarasota, FL), 24 hours prior to ibipinabant exposure. To 
measure mitochondrial membrane potential after 8 hours ibipinabant treatment, cells were loaded with 
100 nM tetramethylrhodamine methyl ester (TMRM) for 25 minutes at 37 °C as described previously42. 
Next, cells were maintained in HT buffer, and images were obtained using a temperature-controlled 
chamber attached to a stage of an inverted microscope (Axiovert 200M, Carl Zeiss, Jena, Germany) 
equipped with a ×63, 1.25 NA Plan NeoFluar oil immersion objective. TMRM intensity analysis was per-
formed on background corrected images, which were masked with a binarised image for mitochondrial 
morphology using Image Pro Plus 6.3 software.
In silico off-target prediction. Since no experimental structure of CB1R is available, a homology 
model was built with the automated protocol of Yasara (version 13.9.8, www.yasara.org)43 and pdb-code 
3v2y as template44. The co-crystallised ligand ML5 of the pdb-entry 3v2y complex is used to define the 
binding site of CB1R for KRIPO and calculate a structure based fingerprint bit string17. This bit string 
was compared to the PDB (version March 2014)45.
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Docking of ibipinabant. The structure of bovine mitochondrial ADP/ATP carrier isoform 1 
(pdb-code 2c3e)46 was used for docking of ibipinabant using Molecular Operating Environment (MOE) 
(version 2013.0802, Chemical Computing Group Inc, Montreal, Canada). The structure preparation and 
protonate 3D protocol of MOE was applied before the docking. Docking was performed using standard 
settings. Ibipinabant was prepared in MOE by assigning PEOE charges and energy minimization.
Mitochondrial ADP uptake assay. ADP transport across the mitochondrial membrane was meas-
ured in isolated bovine heart mitochondria, as described before47,48. Briefly, 10 uL (equal to 130 μ g pro-
tein) mitochondrial pellet was resuspended in ADP import buffer (250 mM sucrose, 20 mM HEPES, pH 
7.2, 10 mM KCl, 5 mM succinate, 3 mM KH2PO4, 1.5 mM MgCl2, 1 mM EGTA, and 5 μ M rotenone) with 
or without the adenine nucleotide translocase inhibitor atractyloside (50 μ M) to inhibit ANT-dependent 
ADP uptake, or with or without DIDS (500 μ M) to inhibit VDAC-dependent ADP uptake. [14C]ADP 
(1 μ Ci) was added to the mitochondrial suspension and incubated for 10 min on ice. After washing 
two times with ADP import buffer, the samples were resuspended in scintillant and quantified using 
a scintillation counter (PerkinElmer Tri-Carb® 2900TR, Perkin Elmer, Waltham, MA). ANT- and 
VDAC-dependent ADP transport activity was determined by the difference in counts between samples 
that respectively were or were not pre-incubated with atractyloside or DIDS. ADP import was decreased 
to 13.8 ± 1.1% and to 8.4 ± 0.8% respectively with atractyloside or DIDS alone.
Statistical analysis. Curve-fitting and statistical analysis was performed using GraphPad prism 5.02 
software (GraphPad Software Inc., San Diego, CA). Unless indicated otherwise, all results are presented 
as mean ± SEM. Differences between groups were tested using one-way ANOVA analysis with appropri-
ate post-hoc tests, unless indicated otherwise.
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